Pharmaceuticals

EU orphan medicines regulation failed

Two decades of EU market protection of ‘orphan’ (rare disease) medicines have greatly benefitted the industry. According to research by The Investigative Desk, published in …

Pharmaceuticals

EMA rewrites medicine approval policy

New innovative medicines should be made available to European citizens more quickly. That is why the European Medicines Agency updates the process for market authorisation. …

Pharmaceuticals

Evergreening the world’s most profitable medicine

Even after the expiration of Humira’s patent protection, AbbVie, the pharmaceutical company, almost completely fended off biosimilar competition for this blockbuster medicine in the Netherlands. …